NewAmsterdam Pharma Co N.V.
NAMS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $4.13B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Other share classesNAMSW
13F holders, Q2 2023
Institutional positions in NewAmsterdam Pharma Co N.V. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 29
- +10 vs. Q1 2023
- Shares held
- 48.8M
- +15.5M (+46.4%) vs. Q1 2023
- Total value
- $580.6M
- +$135.8M (+30.5%) vs. Q1 2023
- New holders
- 11
- 13 more added
- Sold out
- 1
- 1 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAMS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 194 | $4.13B |
| Q1 2026 | 171 | $3.96B |
| Q4 2025 | 187 | $4.19B |
| Q3 2025 | 137 | $3.43B |
| Q2 2025 | 131 | $2.11B |
| Q1 2025 | 126 | $2.28B |
| Q4 2024 | 131 | $2.53B |
| Q3 2024 | 100 | $1.28B |
| Q2 2024 | 90 | $1.38B |
| Q1 2024 | 76 | $1.71B |
| Q4 2023 | 32 | $691.4M |
| Q3 2023 | 35 | $464.1M |
| Q2 2023 | 29 | $580.6M |
| Q1 2023 | 19 | $444.9M |
| Q4 2022 | 14 | $362.2M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding NewAmsterdam Pharma Co N.V.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DuPont Capital Management Corp | 1 | $12 | 0.00% | 00.0% | Unchanged |
| Atticus Wealth Management, LLC | 166 | $1.97K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 183 | $2.18K | 0.00% | +183 | New |
| Wells Fargo & Company | 300 | $3.57K | 0.00% | +300 | New |
| Cutler Group LP | 500 | $5.00K | 0.00% | +500 | New |
| Morgan Stanley | 808 | $9.61K | 0.00% | +305+60.6% | Added |
| Venture Visionary Partners LLC | 10,000 | $118.9K | 0.01% | +10,000 | New |
| JPMorgan Chase & Co | 11,463 | $136.3K | 0.00% | −10,904−48.8% | Reduced |
| Maven Securities LTD | 25,000 | $297.3K | 0.04% | +25,000 | New |
| Marshall Wace, LLP | 25,361 | $301.5K | 0.00% | +25,361 | New |
| Geode Capital Management, LLC | 25,768 | $306.4K | 0.00% | +7,209+38.8% | Added |
| Schonfeld Strategic Advisors LLC | 57,300 | $681.3K | 0.01% | +27,200+90.4% | Added |
| Monashee Investment Management LLC | 95,000 | $1.13M | 0.27% | +95,000 | New |
| Affinity Asset Advisors, LLC | 100,000 | $1.19M | 0.47% | +100,000 | New |
| Alyeska Investment Group, L.P. | 129,547 | $1.54M | 0.01% | +129,547 | New |
| AXA S.A. | 224,351 | $2.67M | 0.01% | +224,351 | New |
| Parkman Healthcare Partners LLC | 239,051 | $2.84M | 0.49% | +124,051+107.9% | Added |
| Millennium Management LLC | 373,552 | $4.44M | 0.00% | +317,919+571.5% | Added |
| Ensign Peak Advisors, Inc | 441,956 | $5.25M | 0.01% | +86,956+24.5% | Added |
| Eversept Partners, LP | 692,369 | $8.23M | 0.87% | +646,513+1,409.9% | Added |
| Adage Capital Partners GP, L.L.C. | 1,200,000 | $14.3M | 0.03% | +1,200,000 | New |
| GMT Capital Corp | 1,383,800 | $16.5M | 0.62% | +300,000+27.7% | Added |
| BVF Inc | 1,521,948 | $18.1M | 0.50% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 2,535,723 | $30.1M | 0.64% | 00.0% | Unchanged |
| Medicxi Ventures Management (Jersey) Ltd | 2,869,565 | $34.1M | 9.56% | +869,565+43.5% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 6,524,565 | $77.6M | 0.32% | +2,608,695+66.6% | Added |
| Ra Capital Management, L.P. | 9,000,000 | $107.0M | 2.02% | +5,000,000+125.0% | Added |
| Bain Capital Life Sciences Investors, LLC | 10,473,913 | $124.5M | 12.83% | +2,173,913+26.2% | Added |
| Frazier Life Sciences Management, L.P. | 10,871,803 | $129.3M | 7.72% | +1,530,252+16.4% | Added |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −4,819−100.0% | Sold out |